CHICAGO, July 27, 2021 /PRNewswire/ -- According to the new market research report "Clinical Trial Imaging Market by Software & Services(Operational Imaging, Read Analysis), Modality(CT, MRI, X-ray, PET, Ultrasound, ECHO), Therapeutic Areas(Infectious, Oncology, CNS, CVS), End user(Pharma, biotechnology, CRO) - Global Forecast to 2026", published by MarketsandMarkets™, the global market is projected to reach USD 1.4 billion by 2026 from USD 1.0 billion in 2021, at a CAGR of 7.6%.
Browse in-depth TOC on "Clinical Trial Imaging Market"
The Increase in R&D spending, growth in pharmaceutical and biotechnology industries and increasing number of CROs are among the other factors. Emerging economies such as China, India and Japan are providing lucrative opportunities for the players operating in the market.
The services segment accounted for the largest share of the market, by product and service segment, in 2020
Based on product and service, the clinical trial imaging market is segmented into services and software. The services segment accounted for the largest share of the market in 2020. Factors such as the and growth in pharmaceutical and biotechnology industries and the increase in R&D spending are contributing for the growth of this market.
Positron emission tomography segment to register the highest growth rate during the forecast period
The clinical trial imaging market is segmented into computed tomography, magnetic resonance imaging, ultrasound, positron emission tomography, X-ray, echocardiography and other modalities. In 2020, the positron emission tomography segment accounted for the highest growth rate. Factors such as the increase in R&D spending, increasing number of CROs and growth in pharmaceutical and biotechnology industries drive this market.
The oncology segment accounted for the largest share of the clinical trial imaging market, by therapeutic area segment, in 2020
Based on therapeutic area, the market has been segmented into oncology, infectious diseases, neurology, CVS, endocrinology, immunological disorder and other therapeutic area. In 2020, the oncology segment accounted for the largest share of the market. An increase in R&D spending and growth in pharmaceutical and biotechnology industries is driving this segments growth.
The pharmaceutical companies segment accounted for the largest share of the market, by end user segment, in 2020
Based on end user, the clinical trial imaging market has been segmented into pharmaceutical companies, biotechnology companies, medical devices manufacturers, contract research organizations, academic and government research institutes and other end users. In 2020, the pharmaceutical companies segment accounted for the largest share of the market. Growth in pharmaceutical and biotechnology companies, increasing number of CROs and increase in R&D spending is driving this segments growth.
North America is the largest regional market for clinical trial imaging market
The global market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the market. The large share of this region can be attributed to increase in R&D spending, increasing number of CROs and growth in pharmaceutical and biotechnology industries.
The major players operating in this clinical trial imaging market are ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), Medpace Holdings, Inc. (US), IXICO plc. (UK), Resonance Health Ltd. (Australia), Radiant Sage LLC. (US), BioClinica Inc. (US), Intrinsic Imaging LLC. (US), Cardiovascular Imaging Technologies LLC. (US), Medical Metrics Inc. (US), Prism Clinical Imaging, Inc. (US), Boston Imaging Core Lab LLC. (US), anagram 4 clinical trials (Spain), Lyscaut Medical Imaging Company (Belgium), Calyx Group (UK), Bioseptive Inc. (Canada), ProScan Imaging LLC. (US), Micron Inc. (Japan), Imaging Endpoints LI, LLC (US), Perspectum Ltd. (UK), Pharmtrace klinische Entwicklung GmbH (Germany), WorldCare Clinical, LLC (US).
Clinical Trial Supplies Market by Services (Manufacturing, Packaging, Logistics, Distribution), Phases (I to IV), Type (Small molecule, Biologics, Medical Devices) Therapeutic Areas (Oncology, CNS, CVD, Infectious, Immunology) - Global Forecast 2026
Contract Research Organization (CROs) Services Market by Type (Early phase, Clinical, Laboratory), Therapeutic Area (Oncology, Infectious Disease), Molecule Type (Vaccine, CGT), End User (Pharma, Biopharma, Research Institute) - Global Forecast to 2026
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets' flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.